GlassScriptPhysician profile
Jill S Mines
NPI 1003840869
$1,720.79
in general payments reported to CMS, 2019-2025
16 companies · $298 in 2025
The $298 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $62.03 · 2022: $337 · 2023: $415 · 2024: $277 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $990.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $402.53 | 2022-2025 | Otezla, Otezla |
| Genzyme Corporation | $322.38 | 2022-2025 | |
| Abbvie INC. | $183.31 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $140.33 | 2019-2023 | Winlevi, Ilumya |
| Merck Sharp & Dohme LLC | $124.58 | 2019 | |
| Leo Pharma INC. | $110.21 | 2019-2025 | Anzupgo |
| Novartis Pharmaceuticals Corporation | $96.38 | 2019-2023 | |
| Lilly USA, LLC | $76.10 | 2019-2020 | |
| Janssen Biotech, INC. | $59.00 | 2025 | Tremfya |
| Allergan, INC. | $45.43 | 2020-2022 | |
| Ucb, INC. | $39.55 | 2020-2023 | Bimzelx |
| Helsinn Therapeutics (U.S.), INC. | $32.89 | 2022-2023 | Valchlor |
| Botanix Sb INC | $28.26 | 2025 | Sofdra |
| Pfizer INC. | $25.65 | 2023 | |
| Organon LLC | $20.42 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $13.77 | 2025 | Opzelura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Mines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.